NCT06086912View on ClinicalTrials.gov

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).

DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).

DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).

Trial Locations (1)

100032

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06086912 - A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites | Biotech Hunter | Biotech Hunter